Analyst consensus rating
Structure Therapeutics Analyst Rating: none
Direct answer
Structure Therapeutics's consensus rating is none.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $105.78.
Forecast evidence checked October 19, 2026.
Get free Structure Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $21.08
- Average price target
- $105.78
- High price target
- $145.00
- Low price target
- $70.00
- Low target gap
- +232.1%
- Target upside
- +401.8%
- High target gap
- +587.9%
- Target range width
- 355.8%
- Consensus rating
- none
- Analysts
- 15
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Structure Therapeutics?
Structure Therapeutics has a verified none consensus. The same dataset has an average price target of $105.78.
How far are Structure Therapeutics's low and high targets from the recorded price?
The low target implies +232.1%, while the high target implies +587.9%.
How many analysts are included in Structure Therapeutics's consensus?
The verified consensus includes 15 analysts.
How is Structure Therapeutics's target upside or downside calculated?
The average target of $105.78 is divided by the recorded price of $21.08, then one is subtracted to produce +401.8%. This does not guarantee a future return.
When was Structure Therapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.